Clinical Trials Logo

Metastatic Colorectal Cancer clinical trials

View clinical trials related to Metastatic Colorectal Cancer.

Filter by:

NCT ID: NCT00252564 Completed - Clinical trials for Metastatic Colorectal Cancer

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.

NCT ID: NCT00207155 Completed - Clinical trials for Metastatic Colorectal Cancer

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

Start date: December 2003
Phase: Phase 1
Study type: Interventional

The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer

NCT ID: NCT00205322 Completed - Clinical trials for Metastatic Colorectal Cancer

Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer

Start date: April 2004
Phase: Phase 2
Study type: Interventional

The combination of oxaliplatin, 5-FU, leucovorin, and capecitabine is hypothesized to retain and potentially improve upon the activity of the FOLFOX regimens. Additionally, the use of an oral rather than an infusional 5-fu regimen represents a clear advantage in terms of both patient convenience and lack of associated catheter-related complications.

NCT ID: NCT00191984 Completed - Clinical trials for Metastatic Colorectal Cancer

A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer

Start date: June 2004
Phase: Phase 2
Study type: Interventional

A non-randomized phase II study to determine the efficacy and safety of the combination of Pemetrexed and Irinotecan every two weeks in metastatic colorectal cancer patients.

NCT ID: NCT00145314 Completed - Clinical trials for Metastatic Colorectal Cancer

FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer

Start date: May 2005
Phase: Phase 3
Study type: Interventional

The main objective of this trial is to explore the effect of combining an established chemotherapy regimen (FLOX), based on 5-fluorouracil, folinic acid, and oxaliplatin (Eloxatin®), with the EGF receptor antibody cetuximab (Erbitux®) in first-line treatment of metastatic colorectal cancer. The trial will investigate two regimens of FLOX plus cetuximab, in which FLOX is given continuously or intermittently, compared to standard FLOX without cetuximab.

NCT ID: NCT00138060 Completed - Clinical trials for Metastatic Colorectal Cancer

Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants

Start date: June 2005
Phase: Phase 4
Study type: Interventional

This study intends to optimize a fluorouracil/irinotecan chemotherapy regimen by the identification of individual thymidylate synthase (TS) and UDP-glucuronosyltransferase 1 (UGT1A1) polymorphisms before the first administration. The results of this identification determine the chemotherapy type: high-dose irinotecan or not.